For example, galantamine, a Food and Drug Administration-approved medication for the treatment of cognitive deficits associated with Alzheimer’s disease, increases synaptic acetylcholine levels by inhibiting acetylcholinesterase, an enzyme that breaks down acetylcholine. This evidence concerns the gene ACHE and Cognitive impairment.